Fresh from grab­bing Shire’s mR­NA work, RaNA dis­clos­es a $51M raise

RaNA Ther­a­peu­tics is well along the way to fi­nanc­ing its next stage of de­vel­op­ment. A day af­ter the RNA spe­cial­ist took for­mal con­trol of Shire’s 9-year-old pro­gram for mes­sen­ger RNA, the biotech dis­closed $51 mil­lion in fresh fi­nanc­ing in an SEC fil­ing.

RaNA CEO Ron Re­naud told me last week that he was halfway through the process of rais­ing a “sub­stan­tial” sum for the com­pa­ny as it boost­ed its em­ploy­ee ros­ter to more than 60 staffers, up from 48. And by that cal­cu­la­tion, he’s now well along the way to rais­ing a mega-round for RaNA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER